Floatz logo

Carboplatin

Ovarian Epithelial Cancer Stage I

Wake Forest University Health SciencesSmall moleculePhase 2Dormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Ovarian Epithelial Cancer Stage I cohort.

Asset / SponsorPhaseRating
Niraparib
CanariaBio Inc.
Phase 2CCC
Trientine
National Cheng-Kung University Hospital
Phase 1/2CCC
Inno-206
National Cheng-Kung University Hospital
Phase 1/2CCC
Avelumab
University of Texas Southwestern Medical Center
Phase 2CCC
IMMUNOGLOBULIN G1, ANTI-(HUMAN CA125 (CARBOHYDRATE ANTIGEN)) (MOUSE MONOCLONAL B43.13.GAMMA.1-CHAIN), DISULPHIDE WITH MOUSE MONOCLONAL B43.13.KAPPA.-CHAIN, DIMER
CanariaBio Inc.
Phase 2CC
Dordaviprone
Ira Winer
Phase 2CC

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →